Cargando…

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc

In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Kandela et al., 2015) that described how we intended to replicate selected experiments from the paper "BET bromodomain inhibition as a therapeutic strategy to target c-Myc" (Delmore et al., 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aird, Fraser, Kandela, Irawati, Mantis, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2017
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245966/ https://www.ncbi.nlm.nih.gov/pubmed/28100400 http://dx.doi.org/10.7554/eLife.21253

Ejemplares similares

Correction: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Aird, Fraser, et al.
Publicado: (2018)

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Kandela, Irawati, et al.
Publicado: (2015)

Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
por: Mantis, Christine, et al.
Publicado: (2017)

Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data
por: Kandela, Irawati, et al.
Publicado: (2017)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
por: Shan, Xiaochuan, et al.
Publicado: (2018)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
por: Fu, Lei-lei, et al.
Publicado: (2015)

Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
por: Shan, Xiaochuan, et al.
Publicado: (2017)

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Replication Study: Transcriptional amplification in tumor cells with elevated c-Myc
por: Lewis, L Michelle, et al.
Publicado: (2018)

BET bromodomain proteins regulate enhancer function during adipogenesis
por: Brown, Jonathan D., et al.
Publicado: (2018)

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
por: Zhang, Zhenfeng, et al.
Publicado: (2016)

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
por: Wyce, Anastasia, et al.
Publicado: (2013)

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
por: Bandopadhayay, Pratiti, et al.
Publicado: (2019)

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
por: Asangani, Irfan A., et al.
Publicado: (2014)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Small molecules remain on target for c-Myc
por: Sun, Linchong, et al.
Publicado: (2017)

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
por: Coleman, Daniel J., et al.
Publicado: (2019)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019)

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
por: Tang, Yujie, et al.
Publicado: (2014)

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma
por: Hensel, Tim, et al.
Publicado: (2015)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

BET bromodomain inhibition suppresses T(H)17-mediated pathology
por: Mele, Deanna A., et al.
Publicado: (2013)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

Registered report: Discovery and preclinical validation of drug indications using compendia of public gene expression data
por: Kandela, Irawati, et al.
Publicado: (2015)

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
por: Song, Shumei, et al.
Publicado: (2020)

Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
por: Groves, Ian J., et al.
Publicado: (2020)

Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitor
por: Alleboina, Satyanarayana, et al.
Publicado: (2021)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms
por: Chan, Gary KL, et al.
Publicado: (2023)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
por: Filippakopoulos, Panagis, et al.
Publicado: (2012)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
por: Wang, Zhi-Qiang, et al.
Publicado: (2023)

Tuning the MYC response
por: Zheng, Ying, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_07o0h7dtu91jggu7prmti09smb